Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Condition: Atrial Fibrillation

This page shows you your search results in order of date. This is page number 10.

Order by Relevance | Date

Total 320 results found since Jan 2013.

Direct Oral Anticoagulant Agents: Pharmacologic Profile, Indications, Coagulation Monitoring, and Reversal Agents
Vitamin K antagonists (VKAs), such as warfarin, have been used for thromboprophylaxis and for the treatment of thromboembolic events in patients with nonvalvular atrial fibrillation for over 60 years. The increasing use of direct oral anticoagulants (DOACs) in recent years has shown greater advantages and safer use over VKA, including reduced bleeding, fewer drug interactions, no food interactions, a quick onset and offset of activity, and predictable dose-response properties. Despite their advantages, there are a couple of major limitations that raise concerns among clinicians, including the need for more coagulation assa...
Source: Journal of Stroke and Cerebrovascular Diseases - May 9, 2018 Category: Neurology Authors: Deborah K. Rose, Barak Bar Tags: Review Article Source Type: research

Is Rivaroxaban a Safe Choice for Apical Thrombus in Atrial Fibrillation Patients? A Case Report
Left ventricular thrombi are mostly seen in the akinetic segments of left ventricle and warfarin is the golden standard treatment. In our case, a 67-year-old male patient with ischemic dilated cardiomyopathy and atrial fibrillation was under warfarin treatment, but due to fluctuations in international normalized ratio, warfarin was discontinued and changed to rivaroxaban (20  mg once a day). He had a fixed thrombus measuring 1.80 × 1.12 cm2 in the left ventricle under warfarin treatment before rivaroxaban use.
Source: Journal of Stroke and Cerebrovascular Diseases - May 4, 2018 Category: Neurology Authors: Fatih Aydin, Ozge Turgay Yildirim, Ayse Huseyinoglu Aydin, Evrin Dagtekin, Ercan Aksit Tags: Case Studies Source Type: research

High Incidence of Occult Atrial Fibrillation in Asian Patients with Cryptogenic Stroke
Occult atrial fibrillation (AF) is not uncommon in patients with stroke. In western cohorts, insertable loop recorders (ILRs) have been shown to be the gold-standard and are cost-effective for AF detection. Anticoagulation for secondary stroke prevention is indicated if AF is detected. The incidence of occult AF among Asian patients with cryptogenic stroke is unclear.
Source: Journal of Stroke and Cerebrovascular Diseases - April 17, 2018 Category: Neurology Authors: Swee-Chong Seow, Ann-Kee How, Siew-Pang Chan, Hock-Luen Teoh, Toon-Wei Lim, Devinder Singh, Wee-Tiong Yeo, Pipin Kojodjojo Source Type: research

Therapeutic Decisions in Atrial Fibrillation for Stroke Prevention: The Role of Aversion to Ambiguity and Physicians' Risk Preferences
Knowledge-to-action gaps influence therapeutic decisions in atrial fibrillation (AF). Physician-related factors are common, but the least studied. We evaluated the prevalence and determinants of physician-related factors and knowledge-to-action gaps among physicians involved in the management of AF patients.
Source: Journal of Stroke and Cerebrovascular Diseases - April 9, 2018 Category: Neurology Authors: Luciano A. Sposato, Devin Stirling, Gustavo Saposnik Source Type: research

Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review
Whether idarucizumab, an antidote of dabigatran, can be used effectively and safely before thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) in patients with stroke undergoing treatment with dabigatran remains unknown. We herein describe a 57-year-old man who developed severe cardioembolic stroke with a National Institutes of Health Stroke Scale score of 22 in the left middle cerebral artery territory while undergoing treatment with dabigatran for nonvalvular atrial fibrillation and who was treated with rt-PA after the reversal of dabigatran with idarucizumab.
Source: Journal of Stroke and Cerebrovascular Diseases - March 16, 2018 Category: Neurology Authors: Yuichiro Ohya, Noriko Makihara, Kayo Wakisaka, Takao Morita, Tetsuro Ago, Takanari Kitazono, Hitonori Takaba Tags: Case Studies Source Type: research

Successful Tissue Plasminogen Activator for a Patient with Stroke After Stanford Type A Aortic Dissection Treatment
Some stroke patients with the acute aortic dissection receiving thrombolysis treatment resulted in fatalities. Thus, the concurrent acute aortic dissection is the contraindication for the intravenous recombinant tissue-type plasminogen activator. However, the safety and the effectiveness of the intravenous recombinant tissue-type plasminogen activator therapy are not known in patients with stroke some days after acute aortic dissection treatment. Here, we first report a case of a man with a cardioembolism due to the nonvalvular atrial fibrillation, who received the intravenous recombinant tissue-type plasminogen activator ...
Source: Journal of Stroke and Cerebrovascular Diseases - March 7, 2018 Category: Neurology Authors: Kosuke Matsuzono, Masayuki Suzuki, Naoto Arai, Younhee Kim, Tadashi Ozawa, Takafumi Mashiko, Haruo Shimazaki, Reiji Koide, Shigeru Fujimoto Tags: Case Studies Source Type: research

A Simple Score That Predicts Paroxysmal Atrial Fibrillation on Outpatient Cardiac Monitoring after Embolic Stroke of Unknown Source
Occult paroxysmal atrial fibrillation (AF) is detected in 16%-30% of patients with embolic stroke of unknown source (ESUS). The identification of AF predictors on outpatient cardiac monitoring can help guide clinicians decide on a duration or method of cardiac monitoring after ESUS.
Source: Journal of Stroke and Cerebrovascular Diseases - February 28, 2018 Category: Neurology Authors: Brittany Ricci, Andrew D. Chang, Morgan Hemendinger, Katarina Dakay, Shawna Cutting, Tina Burton, Brian Mac Grory, Priya Narwal, Christopher Song, Antony Chu, Emile Mehanna, Ryan McTaggart, Mahesh Jayaraman, Karen Furie, Shadi Yaghi Source Type: research

The Dose of Direct Oral Anticoagulants and Stroke Severity in Patients with Acute Ischemic Stroke and Nonvalvular Atrial Fibrillation
The severity and the functional outcome of patients with stroke occurring during off-label underdosing of direct-acting oral anticoagulants (DOACs) remain uncertain.
Source: Journal of Stroke and Cerebrovascular Diseases - February 2, 2018 Category: Neurology Authors: Yuji Kato, Takeshi Hayashi, Norio Tanahashi, Masaki Takao Source Type: research

Left Atrial Appendage Morphology and Embolic Stroke of Undetermined Source: A Cross-Sectional Multicenter Pilot Study
The left atrial appendage (LAA) is the main source of thrombus in atrial fibrillation, and there is an association between non-chicken wing (NCW) LAA morphology and stroke. We hypothesized that the prevalence of NCW LAA morphology would be higher among patients with cardioembolic (CE) stroke and embolic stroke of undetermined source (ESUS) than among those with noncardioembolic stroke (NCS).
Source: Journal of Stroke and Cerebrovascular Diseases - February 2, 2018 Category: Neurology Authors: Shadi Yaghi, Andrew D. Chang, Peter Hung, Brian Mac Grory, Scott Collins, Ajay Gupta, Jacques Reynolds, Caitlin B. Finn, Morgan Hemendinger, Shawna M. Cutting, Ryan A. McTaggart, Mahesh Jayaraman, Audrey Leasure, Lauren Sansing, Nikhil Panda, Christopher Source Type: research

The Dose of Direct Oral Anticoagulants and Stroke Severity in Patients with Acute Ischemic Stroke and Nonvalvular Atrial Fibrillation
The severity and the functional outcome of patients with stroke occurring during off-label underdosing of direct-acting oral anticoagulants (DOACs) remain uncertain.
Source: Journal of Stroke and Cerebrovascular Diseases - February 2, 2018 Category: Neurology Authors: Yuji Kato, Takeshi Hayashi, Norio Tanahashi, Masaki Takao Source Type: research